• ITVI.USA
    15,353.780
    -79.690
    -0.5%
  • OTLT.USA
    2.732
    0.005
    0.2%
  • OTRI.USA
    20.880
    0.030
    0.1%
  • OTVI.USA
    15,332.660
    -75.700
    -0.5%
  • TSTOPVRPM.ATLPHL
    3.280
    -0.020
    -0.6%
  • TSTOPVRPM.CHIATL
    3.190
    0.050
    1.6%
  • TSTOPVRPM.DALLAX
    1.560
    -0.030
    -1.9%
  • TSTOPVRPM.LAXDAL
    3.420
    0.090
    2.7%
  • TSTOPVRPM.PHLCHI
    2.220
    0.050
    2.3%
  • TSTOPVRPM.LAXSEA
    4.080
    0.000
    0%
  • WAIT.USA
    126.000
    1.000
    0.8%
  • ITVI.USA
    15,353.780
    -79.690
    -0.5%
  • OTLT.USA
    2.732
    0.005
    0.2%
  • OTRI.USA
    20.880
    0.030
    0.1%
  • OTVI.USA
    15,332.660
    -75.700
    -0.5%
  • TSTOPVRPM.ATLPHL
    3.280
    -0.020
    -0.6%
  • TSTOPVRPM.CHIATL
    3.190
    0.050
    1.6%
  • TSTOPVRPM.DALLAX
    1.560
    -0.030
    -1.9%
  • TSTOPVRPM.LAXDAL
    3.420
    0.090
    2.7%
  • TSTOPVRPM.PHLCHI
    2.220
    0.050
    2.3%
  • TSTOPVRPM.LAXSEA
    4.080
    0.000
    0%
  • WAIT.USA
    126.000
    1.000
    0.8%
American ShipperCanadaTrade and Compliance

US proposes rule to let states import some Canadian prescription drugs

Food and Drug Administration cites need for lower prices and reduced out-of-pocket costs to U.S. patients.

The U.S. Food and Drug Administration has proposed a rule that, if implemented, would allow states to import certain prescription drugs from Canada.

“The purpose of the proposed rule is to lower prices and reduce out of pocket costs for American patients,” the FDA said in a Federal Register notice expected to be published on Dec. 23.

Under the rule, the program would be implemented through the Federal Food, Drug, and Cosmetic (FD&C) Act’s Section 804 Importation Programs (SIPs) and managed by states or certain non-federal entities. A pharmacist or wholesaler could co-sponsor a SIP.

Each eligible prescription drug import must be approved for use in both Canada and the U.S. and include appropriate labeling.

“The supply chain for each drug under a SIP would be limited to three entities, i.e. one manufacturer, one foreign seller, and one importer,” FDA said.

After the FDA approves a SIP, the U.S. importer must submit a “pre-import request” to the agency at least 30 days before the scheduled date of the prescription drug’s delivery. FDA will dictate at which Customs and Border Protection (CBP) port of entry the drug will arrive in the U.S.

The U.S. importer or its customs broker would be required to electronically file a formal import entry in the CBP’s Automated Commercial Environment (ACE).

“As drug distributors realize savings in acquiring imported drugs and pass some of these savings to consumers and other parties in the drug supply chain, it is possible that U.S. drug manufacturers may experience a transfer in U.S. sales revenues to these parties,” FDA said.

FDA will accept public comments regarding the proposed rulemaking for 75 days after publication in the Federal Register.

Canadians are concerned that the implementation of the FDA regulation will exacerbate a domestic shortage of certain prescription drugs. 

FreightWaves Canadian correspondent Nate Tabak reported in August that a 2018 survey found 67% of Canadian pharmacists dealt with daily shortages of certain prescription medicines.


Chris Gillis

Located in the Washington, D.C. area, Chris Gillis primarily reports on regulatory and legislative topics that impact cross-border trade. He joined American Shipper in 1994, shortly after graduating from Mount St. Mary’s College in Emmitsburg, Md., with a degree in international business and economics.

We are glad you’re enjoying the content

Sign up for a free FreightWaves account today for unlimited access to all of our latest content

By signing in for the first time, I give consent for FreightWaves to send me event updates and news. I can unsubscribe from these emails at any time. For more information please see our Privacy Policy.